Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$22.76M+246.26%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Glendon E. French
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 296
- Beta
- 0.28
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -5.83
Financials
Revenue
$22.76M+246.3%Net Income
$-10.08MEBITDA
$-8.73MFree Cash Flow
$-5.21MEPS (diluted)
$-0.23Shares Outstanding (diluted)
42.18M+2368.1%Operating Expenses
$26.80MCash & Debt
$55.84MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $90.50M | $-54.00M | $-1.33 |
| 2024 | $83.79M | $-56.39M | $-1.44 |
| 2023 | $68.67M | $-60.84M | $-1.60 |
| 2022 | $53.66M | $-58.92M | $-1.59 |
| 2021 | $48.42M | $-48.66M | $-1.35 |
| 2020 | $32.73M | $-32.23M | $-0.90 |
| 2019 | $32.59M | $-20.70M | $-0.58 |
| 2018 | $20.00M | $-18.48M | $-0.89 |
Valuation
LUNGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-33.33%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·34d ago·Negative
…nx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards…
View source ↗ - Newsglobenewswire.com·39d ago·Negative
Pulmonx to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
View source ↗ - Newszacks.com·40d ago·Positive
Pulmonx Corporation (LUNG) Now Trades Above Golden Cross: Time to Buy? After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
View source ↗ - Newsmarketbeat.com·52d ago·Neutral
Pulmonx Rebuilds Sales Force, Targets Growth and AeriSeal Launch Next Year Pulmonx NASDAQ: LUNG is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat.
View source ↗ - Newszacks.com·52d ago·Positive
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now? Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.26 per share
Typical surprise +14.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$-0.24 vs $-0.28beat
- Wed, Apr 29$-0.33 vs $-0.33beat
- Wed, Mar 4$-0.25 vs $-0.39beat
- Wed, Nov 12$-0.34 vs $-0.40beat
- Wed, Jul 30$-0.38 vs $-0.40beat
- Wed, Apr 30$-0.36 vs $-0.37beat
Estimates and results for LUNG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by LUNG officers and directors.
- Bought
- $71k
- Sold
- $854k
1 trade
69 trades
- French Glendon E. Iiisold
- French Glendon E. Iiisold
- Radhakrishnan Srikanthsold
- Radhakrishnan Srikanthsold
- Radhakrishnan Srikanthsold
- Radhakrishnan Srikanthsold
- Lehman David Aaronsold
- Lehman David Aaronsold
30 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in LUNG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.